Previous 10 | Next 10 |
Alzamend Neuro (NASDAQ:ALZN) perks up 2.8% premarket after submitting a pre-IND meeting request for AL002 and supporting briefing documents to FDA's Center for Biological Evaluation and Research. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has submitted a pre-IND mee...
Annovis Bio, Inc. (NYSE:ANVS) -53% after presenting Alzheimer's drug data at AAIC 2021. Atreca, Inc. (NASDAQ:BCEL) -29% after presents initial clinical data from Phase 1b trial of ATRC-101 in select advanced solid tumors. Citrix Systems, Inc. (NASDAQ:CTXS) -16% on Q2 ...
selvanegra/iStock via Getty Images Alzamend Neuro ([[ALZN]] +27.1%) surged after the company announced the receipt of a “study may proceed letter” from the FDA for the company’s Investigational New Drug application ((IND)) for Alzheimer’s candidate AL001. The compa...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced receipt of U.S. Food and Drug...
Alzamend Neuro Inc. (NASDAQ:ALZN) traded today at a new 52-week low of $4.44. Approximately 4.2 million shares have changed hands today, as compared to an average 30-day volume of 3.2 million shares. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on devel...
Shares of biotechnology name Alzamend Neuro (NASDAQ: ALZN) were down on the order of 14.3% in Monday's trading, following through on Friday's intraday reversal of a big news-driven gain. With time to put that news into the proper context, investors still see the company's stock as b...
Shares of Alzamend Neuro (NASDAQ: ALZN) , a biotechnology company in the pre-clinical stage, started Friday's trading 44% higher. Investors were thrilled with the positive results of a mouse toxicology study with an experimental new Alzheimer's disease treatment called AL002. Bu...
selvanegra/iStock via Getty Images Alzamend Neuro (ALZN) has climbed ~77.5% in the pre-market after the company announced positive results for its experimental Alzheimer’s candidate AL002 in a mouse model with the disease. AL002 is a cell-based therapeutic vaccine designed to...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re gearing up for one final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! Source: Shutterstock But hold up just a minute. Let’s r...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...